Microcap Ledger Annexon, Inc. $ANNX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Brisbane, CA
- Fiscal year end
- December 31
What the company doesAI summary of filing
Annexon, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies that inhibit the classical complement pathway, specifically by targeting C1q, to treat complement-mediated neuroinflammatory diseases affecting approximately 10 million people worldwide. The company's pipeline includes two late-stage registrational programs: tanruprubart for Guillain-Barré Syndrome (GBS), for which an MAA was filed with the European Medicines Agency in January 2026, and vonaprument for geographic atrophy (GA), a form of dry age-related macular degeneration, with Phase 3 topline data expected in the fourth quarter of 2026; the company is also developing ANX1502, an oral small molecule for autoimmune conditions. Annexon has no approved products and generates no revenue from product sales; the company has incurred significant losses since inception and anticipates continued losses as it pursues clinical development and regulatory approval of its product candidates. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$99.49M | −$94.80M | $199.27M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | — | −$206.70M | −$186.36M | $162.05M | [DEF 14A 2026-04-27] |
| FY ended Dec 2024 | — | −$138.20M | −$118.01M | $49.50M | [DEF 14A 2026-04-27] |
- Quarterly cash burn
- −$47.40M
- Cash runway Estimate
- ~12.6 months
Capital structure and dilution
- Shelf registration
- S-3ASR filed 2026-03-31 [S-3ASR 2026-03-31]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-24 | Love Douglas | buy | 26,065 | $3.83 | [4 2026-09-25] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Results of operations; Other events |
| 2026-08-10 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-08-07 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 8-K | Other events |
| 2026-07-30 | 8-K | Material agreement entered; New financial obligation; Other events |
| 2026-07-27 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-08 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-08 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-12 | 8-K | Shareholder vote results |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-07 | 10-Q | Quarterly report |
Alerts for $ANNX
Email me when Annexon, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.